Sulphinpyrazone Reduces Deposition of Fibrin on Dialyser Membranes

1979 ◽  
Author(s):  
H.F. Woods ◽  
Gillian Ash ◽  
M.J. WESTON
Keyword(s):  
Platelet Count ◽  
Blood Loss ◽  
Treatment Period ◽  
Control Period ◽  
Antiplatelet Agent ◽  
Plasma Fibrinogen ◽  
Fibrin Deposition ◽  
The Mean ◽  
Residual Blood

Activation of platelets may be responsible for thrombus deposition on dialyser membranes during haemodialysis despite adequate anticoagulation with heparin. This thrombus deposition increases residual blood loss within the dialyser and may impair dialyser efficiency thus limiting the reuse of disposable dialysers. To determine whether the antiplatelet agent sulphinpyrazone reduces such thrombus deposition dialyser 131I-fibrinogen and platelet fibrinogen levels during dialysis were compared in thirteen pairs of dialyses in five patients during a nontreatment control period and while the patients were receiving sulphinpyrazone 200 mg tds. The mean fibrin deposition within the dialysers measured as gram x10-3 of clottable fibrinogen was significantly less during the treatment period (2.5) than during the control period (5.3).Sulphinpyrazone reduced the fall in platelet count during dialysis. Plasma fibrinogen levels during haemodialysis were significantly higher with sulphinpyrazone treatment compared to control dialyses and this difference could not be explained solely by reduction of fibrin deposition on the dialyser membranes. It is probable that sulphinpyrazone reduces fibrinogen consumption within the patient during dialysis as well as within the dialyser membrane itself.

scholarly journals Effect of Cigarette Smoking on Plasma Fibrinogen and Platelet Count

2012 ◽  
Vol 2 (3) ◽  
pp. 181-184 ◽  
Author(s):  
Rashmi Narayanrao Gitte
Keyword(s):  
Platelet Count ◽  
Cigarette Smoking ◽  
Coagulation Factor ◽  
Plasma Fibrinogen ◽  
Fibrinogen Concentration ◽  
Human Beings ◽  
Healthy Male ◽  
The Mean ◽  
Surrounding Areas ◽  
Two Parameters

Objective: Cigarette smoking is one of the major lifestyle factors influencing the health of human beings. Fibrinogen is the major plasma protein coagulation factor. Higher plasma fibrinogen concentrations are associated with cardiovascular diseases. Material & Methods: One hundred twenty healthy male smokers and one hundred twenty healthy male non-smokers among hospital employees and people from surrounding areas of Narayana Medical College, Nellore (India) were studied. The platelet count was done using Beckman Coulter Automatic Analyzer; AcT 5diffCP.Assay for plasma fibrinogen was performed using turbido-metric immunoassay. Results: The mean plasma fibrinogen concentration for smokers is 3.78 gms/L and for non-smokers 3.02 gms/L. The mean platelet count for smokers is 257325 per mm3 and for non-smokers 215483.3 per mm3. The difference between mean plasma fibrinogen and platelet count of smokers and non-smokers was statistically significant (p<0.0001). Conclusion: Thus we concluded that in smokers plasma fibrinogen concentration and platelet count increase significantly. Regular monitoring of these two parameters in smokers is advised DOI: http://dx.doi.org/10.3126/ajms.v2i3.4261 Asian Journal of Medical Sciences 2 (2011) 181-184  

scholarly journals Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 373-373 ◽  
Author(s):  
Flora Peyvandi ◽  
Spero R Cataland ◽  
Marie Scully ◽  
Paul Coppo ◽  
Paul Knöbl ◽  
...  
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Treatment Period ◽  
Phase Ii ◽  
Thromboembolic Event ◽  
Advisory Board ◽  
Phase Iii ◽  
Count Response ◽  
The Mean

Abstract Introduction : Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy, in which accumulation of ultra large von Willebrand factor (ULvWF) multimers leads to an increased risk of thrombus formation in small blood vessels due to platelet adhesion. A combination of plasma exchange (PE) and immunosuppression is the current mainstay of treatment for aTTP. The efficacy of caplacizumab in aTTP patients, in conjunction with PE and immunosuppression, was demonstrated in both placebo-controlled Phase II TITAN study and Phase III HERCULES study. Herein, we present the results of the integrated efficacy analyses of both studies. Methods : All randomized patients in the TITAN and HERCULES studies were integrated and included in the analysis population. Patients had a single-blind (SB, TITAN) or a double-blind (DB, HERCULES) treatment period followed by a follow-up period of 30 days. Patients in the HERCULES study could enter an open-label treatment period (i.e., in case of exacerbation during the DB treatment period). The primary endpoint was time to platelet count response, analyzed according to the corresponding platelet count response definition for each individual study (Figure 1). Secondary endpoints included: (i) the proportion of patients with TTP-related death, a recurrence of TTP, or at least one treatment-emergent major thromboembolic event; (ii) the proportion of patients with a recurrence of TTP during the DB/SB treatment period and the overall study period; (iii) the proportion of patients with refractory TTP (defined as the absence of platelet count doubling after 4 days of standard treatment, and LDH above normal); (iv) mortality rate during the DB/SB treatment period and the overall study period; (v) the number of PE days during the DB/SB treatment period. Results : 220 patients were randomized in both studies, 108 to the caplacizumab group and 112 to the placebo group. The groups were balanced with respect to demographics and baseline disease characteristics except for an imbalance relating to a history of previous TTP episode (Table 1). There was a statistically significant difference in favor of caplacizumab in time to platelet count response (p <0.001; platelet count normalization rate ratio [95% CI] of 1.65 [1.24, 2.20]) (Figure 1, Table 2). Treatment with caplacizumab resulted in a 72.6% reduction in the percentage of patients with TTP-related death, a recurrence of TTP, or at least one treatment-emergent major thromboembolic event during the DB/SB treatment period compared to placebo (p <0.0001) (Table 2). Treatment with caplacizumab resulted in an 84.0% reduction in the percentage of patients who had a recurrence of TTP during the DB/SB treatment period (p <0.0001), and a 49.4% reduction in recurrences during the overall study period (p <0.005), compared to placebo (Table2). No patients in the caplacizumab group had refractory TTP during the DB/SB treatment period compared to 7 patients (6.3%) in the placebo group (p <0.01) (Table 2). There was a statistically significant lower rate of death in the caplacizumab group (no deaths) compared to the placebo group (4 deaths) during the DB/SB treatment period (p <0.05) (Table 2). During the overall study period, one patient randomized to caplacizumab died (during the treatment-free follow-up period, judged unrelated to caplacizumab by the Investigator), compared to 5 patients randomized to placebo (Table 2). During the overall treatment period, there was a reduction in the mean number of PE days of 3.9 days in the caplacizumab group compared to the placebo group (Table 2). Conclusions : This integrated efficacy analyses confirmed results from the individual Phase II and III studies showing that treatment with caplacizumab significantly reduces the time to platelet count response compared to treatment with placebo. In addition, treatment with caplacizumab was associated with clinically meaningful and statistically significant reductions in: (i) the proportion of patients with TTP-related death, a recurrence of TTP, or at least one treatment-emergent major thromboembolic event; (ii) the proportion of patients who died from TTP during the study drug treatment period; (iii) the proportion of patients with a recurrence of TTP during treatment and overall; (iv) the number of patients refractory to therapy; (v) the mean number of days of plasma exchange. Disclosures Peyvandi: Kedrion: Consultancy; Roche: Speakers Bureau; Octapharma US: Honoraria; Kedrion: Consultancy; Ablynx: Other: Member of Advisory Board, Speakers Bureau; Roche: Speakers Bureau; Sobi: Speakers Bureau; Sobi: Speakers Bureau; Octapharma US: Honoraria; Sobi: Speakers Bureau; Roche: Speakers Bureau; Grifols: Speakers Bureau; Roche: Speakers Bureau; Grifols: Speakers Bureau; Novo Nordisk: Speakers Bureau; Shire: Speakers Bureau; Ablynx: Other: Member of Advisory Board, Speakers Bureau; Grifols: Speakers Bureau; Grifols: Speakers Bureau; Roche: Speakers Bureau; Kedrion: Consultancy; Ablynx: Other: Member of Advisory Board, Speakers Bureau; Kedrion: Consultancy; Ablynx: Other: Member of Advisory Board, Speakers Bureau; Novo Nordisk: Speakers Bureau; Sobi: Speakers Bureau; Shire: Speakers Bureau; Novo Nordisk: Speakers Bureau; Octapharma US: Honoraria; Novo Nordisk: Speakers Bureau; Novo Nordisk: Speakers Bureau; Ablynx: Other: Member of Advisory Board, Speakers Bureau; Shire: Speakers Bureau; Shire: Speakers Bureau; Shire: Speakers Bureau; Octapharma US: Honoraria; Grifols: Speakers Bureau; Sobi: Speakers Bureau; Octapharma US: Honoraria; Kedrion: Consultancy. Cataland:Alexion: Research Funding; Shire: Consultancy; Ablynx: Consultancy, Other: Member of Advisory Board. Scully:Novartis: Honoraria, Other: Member of Advisory Board, Speakers Bureau. Coppo:Ablynx: Consultancy. Knöbl:Ablynx: Consultancy, Other: Member of Advisory Board. Kremer Hovinga:Shire: Other: Member of Advisory Board, Research Funding; Ablynx: Other: Member of Advisory Board. Metjian:Ablynx: Other: Member of Advisory Board. De La Rubia:Ablynx: Consultancy, Other: Member of Advisory Board. Minkue:Ablynx: Employment. Callewaert:Ablynx: Employment. De Winter:Ablynx: Employment.

Reduction In Thrombus Formation In Hollow Fiber Artificial Kidney (HFAK) And Improvement Of Dialyser Reuse With Ticlopidine (TCP)

1981 ◽  
Author(s):  
G chong ◽  
Q V Nguyen ◽  
C Mion
Keyword(s):  
Thrombus Formation ◽  
Control Period ◽  
Antiplatelet Agent ◽  
Artificial Kidney ◽  
Weekly Schedule ◽  
Urea Clearance ◽  
Treatment Control ◽  
Major Side Effect ◽  
Single Use ◽  
Residual Blood

To determine whether TCP reduced thrombus formation in HFAK, 2 protocols were used in 20 patients on haemodialysis (HD) for more than 4 months (weekly schedule: 3 × 3-5 hours; Cordis HFAK IV, 1.3 m2; heparin: 25-30 units per kg body weight per hour).In protocol I, the reduction in HFAK fiber bundle volume (ΔFBV) and residual blood volume (RBV) were compared after a single use during a non-treatment control period and while patients were receiving TCP 500 mg/day (9 dialyses in each period). Before TCP, AFBV and RBV were 21.4±14 ml (x±SD) and 21.5±16 ml respectively; on TCP, both parameters were reduced to 2.1±1.5 ml and 3.1±1.9 ml respectively (p<0.01).In protocol II, HFAK Cordis IV was reused as long as the reduction in FBV (controlled before the first and at the end of each dialysis) was less than 20%; urea clearance (Cu) was also measured after each use. Before TCP, reuse frequency (RF) was 1.7±1 per dialyser and Cu dropped from 163±16 ml/mn to 118±23 ml/mn after first use (p<0.01); on TCP, RF was 5.5±1.2 per dialyser without significant Cu variation between first and third utilisation (160±15 Vs 152±16 ml/mn; p=NS).No major side effect was observed and digestive blood loss (measured with 51Cr tagged red blood cells) did not increase significantlyIn conclusion, TCP was shown to be a safe antiplatelet agent in HD patients and to maintain better dialysis performances in HFAK with single and/or multiple uses

scholarly journals Perioperative Blood Loss Can Be Reduced If Total Knee Arthroplasty Was Performed in the Si Hour-Period, Compared with the Wei Hour-Period: A Retrospective Cohort Study

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Xiaojian Wang ◽  
Ting Xu ◽  
Rui Wang ◽  
Penghe Wang ◽  
Shuaijie Jin ◽  
...  
Keyword(s):  
Total Knee Arthroplasty ◽  
Platelet Count ◽  
Postoperative Complications ◽  
Blood Loss ◽  
Transfusion Rate ◽  
Vein Thrombosis ◽  
Group A ◽  
Total Knee ◽  
The Mean ◽  
Group B

Objective. To investigate the efficacy and safety of performing primary unilateral total knee arthroplasty (TKA) in the “Si hour-period” meaning 09:00 a.m. to 11:00 a.m. (one of the 12 two-hour periods into which the day was traditionally divided, each being given the name of one of the 12 earthly branches), compared with the “Wei hour-period” (13:00–15:00). Methods. Patient documentations were studied for those who underwent a primary unilateral TKA performed by the same surgical team with a tourniquet between January 2018 and January 2021 at our medical center. Eighty-four patients were enrolled and assigned into group A (in Si hour-period) and group B (in Wei hour-period). The main outcomes were total blood cell loss (TBL), hidden blood loss (HBL), visible blood loss (VBL), maximum hemoglobin (Hb) drop, and transfusion rate. Secondary outcomes were length of hospital stay (LOS), postoperative femorotibial mechanical axis (FTMA), FTMA correction, platelet count, plasma D-dimer (D-D), prothrombin time (PT), international normalized ratio (INR), and the incidence of postoperative complications. Results. Group A showed statistical significance lower at the mean TBL, the mean HBL, and the maximum Hb drop (95% CI: −352.8 to −46.1, P = 0.011 , 95% CI: −348.0 to −40.1, P = 0.014 , and 95% CI: −9.5 to −0.7, P = 0.023 , respectively) after TKA than group B. The postoperative platelet count of group A was more significant than that of group B (95% CI:3.1 to 52.9, P = 0.028 ). The VBL, transfusion rate, the LOS, postoperative FTMA, FTMA correction, plasma D-D, PT, INR, and the incidence of postoperative complications (wound complications, calf muscular vein thrombosis, infection, pulmonary embolism, and deep vein thrombosis) were similar between the two groups ( P > 0.05 , respectively). Conclusion. Our study shows that blood loss can be reduced when TKA is performed in the “Si hour-period,” which may be due to increasing platelet count, and postoperative complications did not increase, compared with the Wei hour-period. We recommend that the selective operation, such as TKA, should be performed in the “Si hour-period” in clinical practice between the two hour-period.

Fibrin Derivatives, Plasma Hemoglobin and Glomerular Fibrin Deposition in Experimental Intravascular Coagulation

1973 ◽  
Vol 29 (02) ◽  
pp. 363-374 ◽  
Author(s):  
F. K Beller ◽  
W Theiss
Keyword(s):  
Quantitative Measurement ◽  
Plasma Fibrinogen ◽  
Moderate Increase ◽  
Consumption Coagulopathy ◽  
Fibrin Deposition ◽  
Intravascular Coagulation ◽  
Plasma Hemoglobin ◽  
Three Stages ◽  
Two Parameters ◽  
Gelation Test

SummaryPlasma fibrinogen, circulating fibrinmonomers (as indicated by a positive ethanol gelation test), fibrinolysis breakdown products and plasma hemoglobin were assayed in 122 rats subjected to endotoxin injection or infusion. The results were correlated with the quantitative measurement of glomerular fibrin deposition. Based on these data four groups were determined : consumption coagulopathy and three stages of increasing severity of disseminated intravascular coagulation (DIG).Consumption coagulopathy was defined by a decrease in plasma fibrinogen and a positive ethanol gelation test in the absence of glomerular fibrin deposition. Plasma hemoglobin and fibrinolysis breakdown products were normal or only slightly increased.DIG as characterized by glomerular fibrin deposition was defined as moderate (1 to 20% glomeruli showing fibrin strands), intermediate (21 to 80%), and severe (81 to 100%). Decrease in plasma fibrinogen and frequence of a positive ethanol gelation test in all stages of DIG were only slightly different from the findings in consumption coagulopathy. However, a sharp increase in plasma hemoglobin levels was noted when glomerular fibrin deposition did occur even in small amounts. At this time only a moderate increase was noted in fibrin(ogen) breakdown products. These two parameters increased only slightly in the group of intermediate DIG. Severe DIG was characterized by a massive increase in fibrin (ogen) breakdown products and high levels of plasma hemoglobin.

The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery – A Meta-Analysis of Double-Blind, Placebo-Controlled Trials

1995 ◽  
Vol 74 (04) ◽  
pp. 1064-1070 ◽  
Author(s):  
Marco Cattaneo ◽  
Alan S Harris ◽  
Ulf Strömberg ◽  
Pier Mannuccio Mannucci
Keyword(s):  
Cardiac Surgery ◽  
Blood Loss ◽  
Meta Analysis ◽  
Postoperative Blood Loss ◽  
Controlled Trials ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Transfusion Requirements ◽  
The Mean ◽  
Excessive Blood Loss

SummaryThe effect of desmopressin (DDAVP) on reducing postoperative blood loss after cardiac surgery has been studied in several randomized clinical trials, with conflicting outcomes. Since most trials had insufficient statistical power to detect true differences in blood loss, we performed a meta-analysis of data from relevant studies. Seventeen randomized, double-blind, placebo-controlled trials were analyzed, which included 1171 patients undergoing cardiac surgery for various indications; 579 of them were treated with desmopressin and 592 with placebo. Efficacy parameters were blood loss volumes and transfusion requirements. Desmopressin significantly reduced postoperative blood loss by 9%, but had no statistically significant effect on transfusion requirements. A subanalysis revealed that desmopressin had no protective effects in trials in which the mean blood loss in placebo-treated patients fell in the lower and middle thirds of distribution of blood losses (687-1108 ml/24 h). In contrast, in trials in which the mean blood loss in placebo-treated patients fell in the upper third of distribution (>1109 ml/24 h), desmopressin significantly decreased postoperative blood loss by 34%. Insufficient data were available to perform a sub-analysis on transfusion requirements. Therefore, desmopressin significantly reduces blood loss only in cardiac operations which induce excessive blood loss. Further studies are called to validate the results of this meta-analysis and to identify predictors of excessive blood loss after cardiac surgery.

Platelet Adhesiveness and Fibrinolysis after Recent Cerebro-Vascular Accidents and their Relationship with Subsequent Deep Venous Thrombosis of the Legs

1976 ◽  
Vol 36 (01) ◽  
pp. 127-132 ◽  
Author(s):  
C. P Warlow ◽  
J. A. N Rennie ◽  
D Ogston ◽  
A. S Douglas
Keyword(s):  
Platelet Count ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Plasminogen Activator ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Platelet Adhesiveness ◽  
Plasma Fibrinogen Level ◽  
Vascular Accidents ◽  
Subsequent Rise

SummaryIn fifteen patients with a cerebro-vascular accident resulting in an acute hemiplegia there was a subsequent rise in the platelet count and plasma fibrinogen level. There were no significant alterations in platelet adhesiveness, plasminogen activator, plasminogen, FR-antigen and haematocrit. Patients diagnosed as developing deep venous thrombosis with the 125I-fibrinogen technique had a significantly lower platelet adhesiveness and plasminogen level than those who were not.

Acute and Chronic Changes in Platelet Volume and Count After Cardiopulmonary Bypass Induced Thrombocytopenia in Man

1987 ◽  
Vol 57 (01) ◽  
pp. 55-58 ◽  
Author(s):  
J F Martin ◽  
T D Daniel ◽  
E A Trowbridge
Keyword(s):  
Platelet Count ◽  
Mean Platelet Volume ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Control Group ◽  
Artery Bypass Graft ◽  
Platelet Volume ◽  
Young Males ◽  
The Mean

SummaryPatients undergoing surgery for coronary artery bypass graft or heart valve replacement had their platelet count and mean volume measured pre-operatively, immediately post-operatively and serially for up to 48 days after the surgical procedure. The mean pre-operative platelet count of 1.95 ± 0.11 × 1011/1 (n = 26) fell significantly to 1.35 ± 0.09 × 1011/1 immediately post-operatively (p <0.001) (n = 22), without a significant alteration in the mean platelet volume. The average platelet count rose to a maximum of 5.07 ± 0.66 × 1011/1 between days 14 and 17 after surgery while the average mean platelet volume fell from preparative and post-operative values of 7.25 ± 0.14 and 7.20 ± 0.14 fl respectively to a minimum of 6.16 ± 0.16 fl by day 20. Seven patients were followed for 32 days or longer after the operation. By this time they had achieved steady state thrombopoiesis and their average platelet count was 2.44 ± 0.33 × 1011/1, significantly higher than the pre-operative value (p <0.05), while their average mean platelet volume was 6.63 ± 0.21 fl, significantly lower than before surgery (p <0.001). The pre-operative values for the platelet volume and counts of these patients were significantly different from a control group of 32 young males, while the chronic post-operative values were not. These long term changes in platelet volume and count may reflect changes in the thrombopoietic control system secondary to the corrective surgery.

scholarly journals Hematological Profile of HIV-Infected Patients on First-Line Highly Active Antiretroviral Therapy and Its Correlation With CD4 Count

2021 ◽  
Author(s):  
John Jospeh Diamond Princy ◽  
Kshetrimayum Birendra Singh ◽  
Ningthoujam Biplab ◽  
Ningthoukhongjam Reema ◽  
Rajesh Boini ◽  
...  
Keyword(s):  
Platelet Count ◽  
Antiretroviral Therapy ◽  
Hiv Infection ◽  
Highly Active Antiretroviral Therapy ◽  
Cd4 Count ◽  
Total Leukocyte Count ◽  
Hiv Patients ◽  
Positive Correlation ◽  
Highly Active ◽  
The Mean

Abstract Introduction Human immunodeficiency virus (HIV) infection is a state of profound immunodeficiency. Disorders of hematopoietic system are a common but often overlooked complication of HIV infection. This can manifest at any stage of the disease but more commonly in the advanced stage with low CD4 count. Anemia is the most common hematological abnormality in HIV patients and prevalence ranges from 1.3 to 95%. As HIV disease progresses, the prevalence and severity of anemia also increase. Hence, this study was undertaken to assess the hematological parameters of HIV-infected patients on highly active antiretroviral therapy (HAART) at different treatment durations with the hope to improve the HAART outcome in HIV patients and its correlation with CD4 count. Methods This prospective longitudinal study enrolled 134 HIV-infected patients admitted to or attending the OPD in the Department of Medicine or Antiretroviral Therapy (ART) Center (Center of Excellence), Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, from 2018 to 2020. Complete hemogram, CD4 count, and other related-blood investigations were studied. Results The mean age of the study population was 39.9 ± 11.04 years. Of the 134 patients, 75 (56%) were males and 59 (44%) were females. Twelve (9%) patients had a history of injecting drug use (IDU). TLE (tenofovir, lamivudine, efavirenz) regimen was started on 112 (83.6%) patients and the majority of them (69/134 [51.5%]) had a CD4 count of 200 to 499 cells/mm3, which increased significantly 6 months after HAART to 99 to 1,149 cells/mm3, with a mean of 445 ± 217 cells/mm3. There were significant improvements in hemoglobin (Hb) levels, total leukocyte count (TLC), absolute neutrophil count (ANC), and absolute lymphocyte count (ALC) after HAART indicating a positive correlation with CD4 count (p < 0.05). Thrombocytopenia was observed higher after HAART when compared to baseline. There was a positive correlation between platelet count and CD4 count. However, the mean corpuscular volume (MCV) and erythrocyte sedimentation rate (ESR) had a negative correlation with CD4 count. Conclusion The study inferred a strong positive correlation between CD4 and Hb levels, TLC, ANC, ALC, and platelet count after HAART with improvement in these values as CD4 count increases. Specific treatment intervention based on the changes in the immunohematological profile trends can help prevent most of the adverse effects on HIV patients in our community.

scholarly journals Nonstructural bone graft for single-segment lumbar tuberculosis: surgical indications, clinical efficacy, and preliminary experiences in 34 patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098278
Author(s):  
Xing Du ◽  
Yunsheng Ou ◽  
Guanyin Jiang ◽  
Yong Zhu ◽  
Wei Luo ◽  
...  
Keyword(s):  
Blood Loss ◽  
Hospital Stay ◽  
Bone Graft ◽  
Cobb Angle ◽  
Clinical Efficacy ◽  
Operative Time ◽  
Bone Grafts ◽  
Surgical Indications ◽  
Operative Blood Loss ◽  
The Mean

Objective This study was performed to evaluate the surgical indications, clinical efficacy, and preliminary experiences of nonstructural bone grafts for lumbar tuberculosis (TB). Methods Thirty-four patients with lumbar TB who were treated with nonstructural bone grafts were retrospectively assessed. The operative time, operative blood loss, hospital stay, bone graft fusion time, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) concentration, visual analog scale (VAS) score, Oswestry Disability Index (ODI), American Spinal Injury Association (ASIA) impairment grade, and Cobb angle were recorded and analyzed. Results The mean operative time, operative blood loss, hospital stay, Cobb angle correction, and Cobb angle loss were 192.59 ± 42.16 minutes, 385.29 ± 251.82 mL, 14.91 ± 5.06 days, 9.02° ± 3.16°, and 5.54° ± 1.09°, respectively. During the mean follow-up of 27.53 ± 8.90 months, significant improvements were observed in the ESR, CRP concentration, VAS score, ODI, and ASIA grade. The mean bone graft fusion time was 5.15 ± 1.13 months. Three complications occurred, and all were cured after active treatment. Conclusions Nonstructural bone grafts may achieve satisfactory clinical efficacy for appropriately selected patients with lumbar TB.

Sign in / Sign up

Export Citation Format

Share Document